Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.
about
Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson's DiseaseContinuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy studyPopulation pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tabletsContinuous drug delivery in Parkinson's disease.Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safetyIntegrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials.Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study.Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience.Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessmentClinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs.Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration.Continuous infusion of levodopa-carbidopa intestinal gel in Parkinson's disease.Carbidopa levodopa enteral suspension.Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.Novel Levodopa Formulations for Parkinson's Disease.Effect of levodopa-carbidopa intestinal gel on resting tremors in patients with advanced Parkinson's diseaseLevodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa.Effect of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Patients with Advanced Parkinson's Disease.Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?
P2860
Q27325443-878FDF40-9677-41DD-85BC-8A13B2D4961EQ30366253-6B7244B9-30C2-4378-95A5-C0B8DA7339DBQ34209542-A942EF6E-E19D-47CD-823F-4A7A14FD454FQ34390800-1D9BC1E1-1C54-43C6-BA11-D49A05192202Q36025896-75D5A9E4-41C4-4CB4-97AA-12D7D80FE1D8Q37340428-3F41413A-5E53-4645-8743-F59EE1BDD96AQ37342303-CF77C986-889A-4791-AB62-C76ECBF1B678Q37698585-A6137001-D00E-4B3C-BA4B-4F041D1EEE56Q37742224-C206A9A4-82A1-4F45-952F-41AD6EE9A4C9Q38179453-65C98F8D-07C7-4D72-A1E2-96150E0F785AQ38194569-E75D2AC5-13D4-4F61-83C2-8D63EF401527Q38256055-30B58F03-1BA8-4A19-9C20-23C64FAA2613Q38643494-7CF351B0-20EC-4990-8506-2FFF30C75607Q38823793-FB8B5EDC-312C-45CB-A0C4-A3CBE07B8A87Q38981419-3A2F1498-0695-4843-AC95-E6101FDF2C8FQ41055649-88654A2E-9D52-45A0-A837-D34DED1AB5DFQ42254695-2A02F3AC-A842-4064-99A2-0C88F253F84EQ47120831-FB7F83BC-35E2-4151-95D1-C2B15154539CQ47652358-E3A4A40F-4931-48A4-A1F7-FEBA0ECFF669
P2860
Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Pharmacokinetics of levodopa, ...... Parkinson's disease patients.
@en
type
label
Pharmacokinetics of levodopa, ...... Parkinson's disease patients.
@en
prefLabel
Pharmacokinetics of levodopa, ...... Parkinson's disease patients.
@en
P2093
P2860
P1433
P1476
Pharmacokinetics of levodopa, ...... Parkinson's disease patients.
@en
P2093
Ahmed A Othman
Anders Johansson
Charles Locke
Dag Nyholm
Krai Chatamra
Sandeep Dutta
P2860
P2888
P304
P356
10.1208/S12248-012-9439-1
P407
P50
P577
2012-12-11T00:00:00Z
P5875
P6179
1044054383